Non Small Cell Lung Cancer Clinical Trials in Nashville, Tennessee

51 studies are recruiting for non small cell lung cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

  1. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Tennessee Oncology, Nashville, Tennessee
    Locations
    186 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI-Nashville, Nashville, Tennessee
    Locations
    260 in total
    Run by
    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

  3. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Nashville, Tennessee
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

  4. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    52 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

  5. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage
    Phase 2
    Ages
    18 to 95
    Site
    Research Site, Nashville, Tennessee
    Locations
    97 in total
    Run by
    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

  6. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    One Oncology - Tennessee Oncology ( Site 4019), Nashville, Tennessee
    Locations
    229 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

  7. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    47 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT04895709 on ClinicalTrials.gov

  8. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    440 in total
    Run by
    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

  9. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
    Locations
    66 in total
    Run by
    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

  10. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University School of Medicine, Nashville, Tennessee
    Locations
    42 in total
    Run by
    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

  11. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tennessee Oncology, Nashville, Tennessee
    Locations
    10 in total
    Run by
    Compass Therapeutics

    See if you can join NCT06150664 on ClinicalTrials.gov

  12. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute - Nashville, Nashville, Tennessee
    Locations
    47 in total
    Run by
    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

  13. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Locations
    75 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov

  14. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

  15. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    15 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

  16. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    12 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

  17. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    17 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

  18. Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

    This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    6 in total
    Run by
    Phanes Therapeutics

    See if you can join NCT05431270 on ClinicalTrials.gov

  19. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    6 in total
    Run by
    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

  20. Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

    Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and meta…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    Run by
    Jessica Mezzanotte Sharpe

    See if you can join NCT07555210 on ClinicalTrials.gov

  21. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    14 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

  22. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    Locations
    11 in total
    Run by
    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov

  23. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon - Tennessee Oncology, Nashville, Tennessee
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  24. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Nashville, Tennessee
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  25. A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

    This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    7 in total
    Run by
    Avistone Biotechnology Co., Ltd.

    See if you can join NCT06046495 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.